Plasmodium immune treatment for breast and liver cancers
Part of Cancer, Infections clinical trials.
This early-phase study tests an immune-based treatment (using Plasmodium) for people with advanced breast cancer or advanced liver cancer. It aims to see whether the treatment is safe and whether it can help the body’s immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–70 years old and can give informed consent.
- You have advanced breast cancer or advanced liver cancer confirmed by scans and biopsy, with measurable tumor spots on imaging.
- You’ve already had at least one standard cancer treatment, and you’re done with chemotherapy, radiation, or targeted drugs long enough ago (at least 1 month, or at least 5 drug “half-lives”).
- Your heart tracing is acceptable (ECG score 0 or 1) and you’re expected to live at least 6 more months.
- Your blood counts are high enough (platelets, neutrophils, and hemoglobin) and your red blood cells don’t have certain severe disorders.
- Your organ function and immune function are close to normal, and you’re well enough to attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
This trial tests Plasmodium immunotherapy in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the treatment can slow tumor growth or improve cancer control.
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
This Phase 1/2 study tests an immune treatment made from Plasmodium (a malaria-related organism) in people with advanced solid cancers. It aims to see how well the treatment can control tumors and is primarily focused on early safety and whether it shows signs of benefit.
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
This trial tests the safety and immune response of an experimental vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Healthy adults aged 18–59 who have never had malaria may be able to join.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.